National Vaccine
Information Center

Your Health. Your Family. Your Choice.

MedAlerts Home
Search Results

This is VAERS ID 350028

History of Changes from the VAERS Wayback Machine

First Appeared on 12/8/2009

350028
VAERS Form:
Age:22.0
Gender:Female
Location:Foreign
Vaccinated:2009-02-06
Onset:2009-02-27
Submitted:2009-06-24
Entered:2009-06-24
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HEP: HEP B (ENGERIX-B) / GLAXOSMITHKLINE BIOLOGICALS - / - UN / IM

Administered by: Other      Purchased by: Other
Symptoms: Papilloedema, Optic neuropathy

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit? (V2.0) No
Hospitalized? Yes, days: 0     Extended hospital stay? No
Previous Vaccinations:
Other Medications:
Current Illness: Unknown
Preexisting Conditions:
Allergies:
Diagnostic Lab Data: UNK
CDC 'Split Type': B0579359A

Write-up:This case was reported by a regulatory authority (MP20090384, MP0900293) and described the occurrence of optic neuropathy in a 22-year-old female subject who was vaccinated with ENGERIX B (GlaxoSmithKline), GARDASIL (non-GSK). Medical conditions and concurrent medications were unspecified. Previous vaccination included an unspecified dose of GARDASIL given in December 2008. On 06 February 2009, the subject received unspecified dose of ENGERIX B (intramuscular, injection site and batch unknown). In February 2009, on unspecified date, the subject received unspecified dose of GARDASIL (intramuscular, injection site and batch unknown). On 27 February 2009, less than one month after vaccination with GARDASIL and 21 days after vaccination with ENGERIX B, the subject experienced optic neuropathy and papilloedema (NOS). On 06 March 2009, the subject received another dose of ENGERIX B (intramuscular, injection site and batch unknown). The regulatory agency noticed that the events led to hospitalisation and or prolonged hospitalisation. At the time of reporting, the events were improved. The regulatory authority considered optic neuropathy and papilloedema as unlikely related to vaccination with ENGERIX B and GARDASIL, according to the method of imputability.


Changed on 9/14/2017

350028 Before After
VAERS Form:(blank) 1
Age:22.0
Gender:Female
Location:Foreign
Vaccinated:2009-02-06
Onset:2009-02-27
Submitted:2009-06-24
Entered:2009-06-24
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HEP: HEP B (ENGERIX-B) / GLAXOSMITHKLINE BIOLOGICALS - / - UNK UN / IM

Administered by: Other      Purchased by: Other
Symptoms: Papilloedema, Optic neuropathy

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit? (V2.0) No
Hospitalized? Yes, days: 0     Extended hospital stay? No
Previous Vaccinations:
Other Medications:
Current Illness: Unknown
Preexisting Conditions:
Allergies:
Diagnostic Lab Data: UNK
CDC 'Split Type': B0579359A

Write-up:This case was reported by a regulatory authority (MP20090384, MP0900293) and described the occurrence of optic neuropathy in a 22-year-old female subject who was vaccinated with ENGERIX B (GlaxoSmithKline), GARDASIL (non-GSK). Medical conditions and concurrent medications were unspecified. Previous vaccination included an unspecified dose of GARDASIL given in December 2008. On 06 February 2009, the subject received unspecified dose of ENGERIX B (intramuscular, injection site and batch unknown). In February 2009, on unspecified date, the subject received unspecified dose of GARDASIL (intramuscular, injection site and batch unknown). On 27 February 2009, less than one month after vaccination with GARDASIL and 21 days after vaccination with ENGERIX B, the subject experienced optic neuropathy and papilloedema (NOS). On 06 March 2009, the subject received another dose of ENGERIX B (intramuscular, injection site and batch unknown). The regulatory agency noticed that the events led to hospitalisation and or prolonged hospitalisation. At the time of reporting, the events were improved. The regulatory authority considered optic neuropathy and papilloedema as unlikely related to vaccination with ENGERIX B and GARDASIL, according to the method of imputability.


New Search

Link To This Search Result:

http://www.medalerts.org/vaersdb/findfield.php?IDNUMBER=350028&WAYBACKHISTORY=ON


Copyright © 2018 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166